… effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure
… without type 2 diabetes, reporting the effects of dapagliflozin on HF hospitalization, kidney …

Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening
heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined …

… and Prevention of Adverse-Outcomes in Heart Failure), sodium–glucose cotransporter-… heart
failure and reduced ejection fraction. In this analysis, we examine the effects of dapagliflozin …

… However, the overall effects of dapagliflozin in patients … effects of dapagliflozin against HF.
We aimed to conduct a meta-analysis to comprehensively estimate the effects of dapagliflozin …

… The effects of dapagliflozin on the primary composite outcome, each of the individual
mortality and hospital admission outcomes, and on urgent visits for worsening heart failure …

… Finally, the effects of dapagliflozin on major adverse cardiac events and the renal-specific
outcome did not differ by HF subgroup (Figure IV in the online-only Data Supplement). …

… These beneficial effects of dapagliflozin in heart failure with reduced ejection fraction may …
Effects of dapagliflozin versus placebo on the primary end points.A, Effects of dapagliflozin vs …

… in patients with heart failure (HF) … effects of dapagliflozin in HFrEF patients with and without
COPD enrolled in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure …

… Concern about hypotension often leads to withholding of beneficial therapy in patients with
heart failure and reduced ejection fraction (HFrEF). We evaluated the efficacy and safety of …

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for
heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but …